Loading...
In three industry-sponsored, placebo-controlled, randomized trials, injected semaglutide — given weekly with a target dose of 2.4 mg — resulted in substantial weight loss in patients without diabetes who were overweight or obese (NEJM JW Gen Med Mar 15 2021 and N Engl J Med 2021 384;989; NEJM JW Gen Med Apr 1 2021 and JAMA 2021; 325:1403; JAMA 2021;325:1414). Nearly half (about 1500) of the participants had prediabetes, and the rest had normoglycemia.
In this post hoc analysis, researchers sought to determine the proportion of participants with prediabetes at baseline that had achieved normoglycemia (i.e., glycosylated hemoglobin [HbA1c] <5.7% or blood glucose <100 mg/dL) by the end of the trials. Notably, both the semaglutide and placebo gr…